Bacil Pharma Approves ₹50 Cr Rights Issue, Capital Increase

Bacil Pharma Ltd's Board of Directors has approved a proposal to raise funds up to ₹50 crore through a Rights Issue of equity shares. The board also approved an increase in the company's authorized share capital by ₹45 crore to ₹65 crore, subject to shareholder approval. Intermediaries for the Rights Issue, including a registrar, banker, and monitoring agency, have been appointed. Additionally, the board accepted the resignation of two independent directors and formed a Rights Issue Committee. The trading window will remain closed until 48 hours after the board meeting outcome is declared.